Cargando…

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori

Eradication of Helicobacter pylori (H. pylori) is an effective strategy for preventing various gastrointestinal diseases such as gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. However, the eradication success rate is decreasing because of a recent increase in drug-resistant st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Yoshimasa, Konno, Kaho, Sato, Moeka, Nakano, Masaru, Kato, Yukako, Saito, Hidetsugu, Serizawa, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356600/ https://www.ncbi.nlm.nih.gov/pubmed/30669474 http://dx.doi.org/10.3390/cancers11010116

Ejemplares similares

Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy
por: Sue, Soichiro, et al.
Publicado: (2021)

Efficacy of Vonoprazan for Helicobacter pylori Eradication
por: Kiyotoki, Shu, et al.
Publicado: (2019)

Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019)

RE: Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
por: Kusunoki, Maho, et al.
Publicado: (2019)

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023)

Vonoprazan-Associated Gastric Mucosal Redness in Non-Helicobacter pylori-Infected and Helicobacter pylori-Eradicated Stomach
por: Kubo, Kimitoshi, et al.
Publicado: (2021)

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
por: Sue, Soichiro, et al.
Publicado: (2017)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Kashani, Negin, et al.
Publicado: (2018)

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Sue, Soichiro, et al.
Publicado: (2018)

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori
por: Yang, Faming, et al.
Publicado: (2023)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy
por: Miftahussurur, Muhammad, et al.
Publicado: (2020)

The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study
por: Lin, Yimin, et al.
Publicado: (2022)

Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis
por: Zhang, Wen-Lin, et al.
Publicado: (2023)

The efficacy and safety of vonoprazan–amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis
por: Feng, Jia-Hui, et al.
Publicado: (2023)

Current Status of the Third-Line Helicobacter pylori Eradication
por: Choi, Jae Ho, et al.
Publicado: (2018)

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication
por: Sue, Soichiro, et al.
Publicado: (2017)

Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
por: Suzuki, Sho, et al.
Publicado: (2023)

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication
por: Hu, Yi, et al.
Publicado: (2022)

A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance
por: Adachi, Kazunori, et al.
Publicado: (2023)

Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication
por: Nishizawa, Toshihiro, et al.
Publicado: (2009)

Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
por: Saito, Yoshimasa, et al.
Publicado: (2012)

Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: A single‐arm, interventional study
por: Sue, Soichiro, et al.
Publicado: (2022)

Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study
por: Gunaratne, Anoja W, et al.
Publicado: (2021)

Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection
por: Yu, Jing, et al.
Publicado: (2023)

Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen
por: Inokuchi, Kazumi, et al.
Publicado: (2022)

Correction: Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
por: Saito, Yoshimasa, et al.
Publicado: (2013)

Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study
por: Choi, Youn I, et al.
Publicado: (2021)

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
por: Tanabe, Hiroki, et al.
Publicado: (2018)

Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy
por: Hirata, Kenro, et al.
Publicado: (2013)

Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial
por: Zuberi, Bader Faiyaz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_710q42pf2eon6l436dqf70p1sc